Internal Reference Number: FOI_6322
Date Request Received: 11/10/2021 00:00:00
Date Request Replied To: 05/11/2021 00:00:00
This response was sent via: By Email
Request Summary: New biologic medications for the treatment of dermatological and rheumatological conditions
Request Category: Companies
| Question Number 1: How many patients were treated in September 2021 (or latest available month) by the dermatology department with the following drugs: 鈥� Abrocitinib (Cibinqo) 鈥� Baricitinib (Olumiant) 鈥� Bimekizumab (Bimzelx) 鈥� Brodalumab (Kyntheum) 鈥� Dupilumab (Dupixent) 鈥� Ixekizumab (Taltz) 鈥� Risankizumab (Skyrizi) 鈥� Guselkumab (Tremfya) 鈥� Secukinumab (Cosentyx) 鈥� Tildrakizumab (Ilumetri) 鈥� Tralokinumab (Adtralza) 鈥� Ustekinumab (Stelara) | |
| Answer To Question 1: Abrocitinib 0 Baricitinib 0 Bimekizumab 0 Brodalumab 7 Dupilumab 8 Ixekizumab 4 Risankizumab 0 Guselkumab 9 Secukinumab 3 Tildrakizumab 0 Tralokinumab 0 Ustekinumab 15 | |
| Question Number 2: How many patients were treated in September 2021 (or latest available month) by the rheumatology department with the following drugs: 鈥� Baricitinib (Olumiant) 鈥� Filgotinib (Jyseleca) 鈥� Guselkumab (Tremfya) 鈥� Ixekizumab (Taltz) 鈥� Secukinumab (Cosentyx) 鈥� Tofacitinib (Xeljanz) 鈥� Upadacitinib (Rinvoq) 鈥� Ustekinumab (Stelara) | |
| Answer To Question 2: Baricitinib 65 Filgotinib 0 Guselkumab 0 Ixekizumab 23 Secukinumab 19 Tofacitinib 27 Upadacitinib 19 Ustekinumab 6 | |
| To return to the list of all the FOI requests please click here |
Our staff at SA国际传媒 Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
